Free tool
FAERS Monitor: Casporyn Hc
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 060613 or its brand name (Casporyn Hc, Hydrocortisone, Neomycin Sulfate, Polymyxin B Sulfate). Reports on generic versions are filed under their own applications.
Reports
18
Serious
2
11% of reports
Hospitalization
0
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- medication error9
- eye irritation5
- ear pain4
- hypoacusis4
- ear discomfort3
- drug hypersensitivity2
- ocular hyperaemia2
- abnormal sensation in eye1
- balance disorder1
- chills1
- dysphonia1
- ear pruritus1
- erythema of eyelid1
- eustachian tube obstruction1
- eye discharge1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 15 |
| 2008 | 1 |
| 2020 | 1 |
| 2022 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,141 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| eustachian tube obstruction | 1 | 7175.9 | 1061.6 | 1,782 |
| ear discomfortSignal | 3 | 341.7 | 121.6 | 707 |
| ear pruritus | 1 | 333.3 | 49.6 | 82 |
| abnormal sensation in eye | 1 | 271.9 | 40.5 | 67 |
| ear painSignal | 4 | 240.5 | 101.3 | 730 |
| erythema of eyelid | 1 | 215.8 | 32.1 | 53 |
| medication errorSignal | 9 | 189.2 | 119.2 | 1,506 |
| eye discharge | 1 | 112.5 | 16.7 | 27 |
| hypoacusisSignal | 4 | 108.6 | 45.7 | 326 |
| eye irritationSignal | 5 | 101.5 | 48.2 | 403 |
| ocular hyperaemia | 2 | 49.2 | 13.3 | 53 |
| dysphonia | 1 | 20.0 | 3.0 | 4 |
| balance disorder | 1 | 13.5 | 2.0 | 2 |
| drug hypersensitivity | 2 | 12.1 | 3.3 | 11 |
| chills | 1 | 10.0 | 1.5 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.